Prof. Li Zhang 张莉
Chief Physician, Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and radiotherapy for lung, esophageal, breast, gastric, and colorectal cancers. Specializes in molecular targeted therapy for tumors.
Dr. Zhang is a Chief Physician, Professor, and MD with a master’s supervisor role. Trained at Tsinghua University and Peking Union Medical College. Completed a two-year visiting scholar program at Virginia Commonwealth University School of Medicine. Published over ten papers in international oncology journals and serves as a reviewer for multiple international journals. Member of ASCO.
Professional roles
- Member, Lung Cancer Professional Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Youth Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member and Secretary, Oncology Branch, Hubei Medical Doctor Association
- Vice Chair, Radiotherapy Professional Committee, Hubei Clinical Oncology Society
Name order: in Chinese the family name comes first (Zhang Li). Papers usually list the name as Li Zhang or Zhang L.
Selected publications
142 papers on PubMed matched by name and affiliation; 35 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Mol Sci, 2026 (senior author): Spatial Immune Coding in Tumor-Draining Lymph Nodes: Functional Compartmentalization of Immune Activation and Immunosuppression. PubMed 42653118
- JAMA, 2026 (senior author): Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial. PubMed 42307937
- Respir Res, 2026 (senior author): Early radiotherapy delays acquired gefitinib resistance in EGFR-mutant NSCLC by suppressing c-FOS-associated survival signaling. PubMed 42426756
- Biochim Biophys Acta Rev Cancer, 2026 (senior author): Cancer-associated fibroblasts in non-small cell lung cancer therapy: Challenges and opportunities. PubMed 41765207
- J Gerontol A Biol Sci Med Sci, 2026 (first author): Moving geroscience forward in China: proceedings of the first international exchange forum of the Chinese Geriatrics Society. PubMed 41692982
- Dermatol Ther (Heidelb), 2026 (first author): Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD Registry. PubMed 41670770
- Qual Life Res, 2025 (senior author): Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis. PubMed 41313568
- Cancer Immunol Immunother, 2025 (senior author): Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma. PubMed 40531216
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion